Changes in US stocks | Burning Stone Medicine (BNR.US) rose 24% to focus on genetic testing for cancer patients

Zhitongcaijing · 3d ago

The Zhitong Finance App learned that on Tuesday, Burning Stone Medicine (BNR.US) rose 24% to 3.61 US dollars, and the latest market capitalization reached 370.34 million US dollars. According to reports, Burnstone Medicine focuses on genetic testing for cancer patients, covering scenarios such as targeted therapy and immunotherapy, and provides multi-gene parallel testing services to help make clinical medication decisions. The EGFR exon20ins companion diagnostic kit developed by the company in collaboration with Digel Pharmaceuticals was approved in October 2024, becoming the first lung cancer companion diagnostic product based on NGS technology in China.